New Legacy Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

New Legacy Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$205K	Hold	2,805	–	–	0.56%	27
2023 Q2	$233K	Hold	2,805	–	–	0.59%	26
2023 Q1	$214K	Hold	2,805	–	–	0.61%	26
2022 Q4	$233K	Hold	2,805	–	–	0.72%	27
2022 Q3	$222K	Hold	2,805	–	–	0.57%	27
2022 Q2	$208K	Hold	2,805	–	–	0.42%	27
2022 Q1	$252K	Sell	2,805 -2,700	-49%	-$249K	0.09%	28
2021 Q4	$616K	Buy	+5,505	New	+$664K	0.12%	17

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

New Legacy Group's XBI Position: Q3 2023 in Review

New Legacy Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2023 at 2,805 shares worth $205K. The position accounts for 0.56% of the portfolio, ranked #27.

New Legacy Group first reported a position in XBI in Q4 2021 and has held it in 8 quarters since. The position peaked at $616K in Q4 2021. 679 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

New Legacy Group held 2,805 shares of State Street SPDR S&P Biotech ETF worth $205K as of Q3 2023.
New Legacy Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2023.
State Street SPDR S&P Biotech ETF made up 0.56% of New Legacy Group's portfolio in Q3 2023, its #27 holding.
New Legacy Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and has held it in 8 quarters since.
New Legacy Group's State Street SPDR S&P Biotech ETF position peaked at $616K in Q4 2021.
679 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on New Legacy Group's 13F filing for Q3 2023, filed 14 Nov 2023.